Studies Towards a Reversible EGFR C797S Triple Mutant Inhibitor Series
收藏资源简介：
Studies Towards a Reversible EGFR C797S Triple Mutant Inhibitor Series Descriptor: 5-chloranyl-~{N}2-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxy-5-(1-methylpyrazol-4-yl)phenyl]-~{N}4-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine, Epidermal growth factor receptor Authors: Hargreaves, D. Deposit date: 2020-09-17 Release date: 2021-06-02 Last modified: 2024-05-01 Method: X-RAY DIFFRACTION (2.65 Å) Cite: Abstract 4451: Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation Cancer Res., 79, 2019
针对可逆性表皮生长因子受体（Epidermal growth factor receptor, EGFR）C797S三突变体抑制剂系列的研究 描述物：5-氯-N²-[4-[4-(二甲氨基)哌啶-1-基]-2-甲氧基-5-(1-甲基吡唑-4-基)苯基]-N⁴-(2-二甲基膦酰苯基)嘧啶-2,4-二胺 作者：Hargreaves, D. 提交日期：2020-09-17 发布日期：2021-06-02 最后修改日期：2024-05-01 实验方法：X射线衍射（分辨率2.65埃） 引用文献：摘要4451：《携带EGFR C797S突变的肿瘤中氧化膦吡唑类抑制剂的治疗潜力评估》，《癌症研究》（Cancer Res.），79卷，2019年
